Meta-epidemiological review identified variable reporting and handling of time-to-event analyses in publications of trials included in meta-analyses of systematic reviews

Leung, 1997, Censoring issues in survival analysis, Annu Rev Publ Health, 18, 83, 10.1146/annurev.publhealth.18.1.83 Lagakos, 1979, General right censoring and its impact on the analysis of survival data, Biometrics, 35, 139, 10.2307/2529941 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Tierney, 2007, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials, 8, 16, 10.1186/1745-6215-8-16 Kleinbaum, 2012 Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 Higgins Hernán, 2010, The hazards of hazard ratios, Epidemiology, 21, 13, 10.1097/EDE.0b013e3181c1ea43 Stensrud, 2020, Why test for proportional hazards?, JAMA, 323, 1401, 10.1001/jama.2020.1267 Rulli, 2018, Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint, Br J Cancer, 119, 1456, 10.1038/s41416-018-0302-8 Austin, 2017, Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement, Stat Med, 36, 1203, 10.1002/sim.7215 Schumacher, 2016, Competing risk bias was common in a prominent medical journal, J Clin Epidemiol, 80, 135, 10.1016/j.jclinepi.2016.07.013 Sullivan, 2020, Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting, Value Health, 23, 388, 10.1016/j.jval.2019.10.015 Ishak, 2014, Methods for adjusting for bias due to crossover in oncology trials, Pharmacoeconomics, 32, 533, 10.1007/s40273-014-0145-y Goldkuhle, 2021, GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes-Study limitations due to censoring of participants with missing data in intervention studies, J Clin Epidemiol, 129, 126, 10.1016/j.jclinepi.2020.09.017 Zhu, 2017, Reporting and methodological quality of survival analysis in articles published in Chinese oncology journals, Medicine, 96, 10.1097/MD.0000000000009204 Abraira, 2013, Reporting quality of survival analyses in medical journals still needs improvement. A minimal requirements proposal, J Clin Epidemiol, 66, 1340, 10.1016/j.jclinepi.2013.06.009 Altman, 1995, Review of survival analyses published in cancer journals, Br J Cancer, 72, 511, 10.1038/bjc.1995.364 Batson, 2016, Review of the reporting of survival analyses within randomised controlled trials and the implications for meta-analysis, PLoS One, 11, 10.1371/journal.pone.0154870 Mathoulin-Pelissier, 2008, Survival end point reporting in randomized cancer clinical trials: a review of major journals, J Clin Oncol, 26, 3721, 10.1200/JCO.2007.14.1192 Salika, 2022, Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane Database of Systematic Reviews, BMC Med Res Methodol, 22, 73, 10.1186/s12874-022-01541-9 Murad, 2017, Guidelines for reporting meta-epidemiological methodology research, BMJ Evidence-based Medicine, 22, 139, 10.1136/ebmed-2017-110713 Kahale, 2020, Meta-analyses proved inconsistent in how missing data were handled across their included primary trials: a methodological survey, Clin Epidemiol, 12, 527, 10.2147/CLEP.S242080 Page, 2016, Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study, PLoS Med, 13, 10.1371/journal.pmed.1002028 Goldkuhle, 2018, A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer, BMJ Open, 8, 10.1136/bmjopen-2017-020869 Vervölgyi, 2011, Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey, BMC Med Res Methodol, 11, 130, 10.1186/1471-2288-11-130 Butcher, 2022, Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension, JAMA, 328, 2252, 10.1001/jama.2022.21022 Morris, 2019, Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate, BMJ Open, 9, 10.1136/bmjopen-2019-030215 Schulz, 2010, CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials, BMC Med, 8, 18, 10.1186/1741-7015-8-18